A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.

ABSTRACT:

Introduction

The Oncotype DX assay was recently reported to predict risk for distant recurrence among a clinical trial population of tamoxifen-treated patients with lymph node-negative, estrogen receptor (ER)-positive breast cancer. To confirm and extend these findings, we evaluated the performance of this 21-gene assay among node-negative patients from a community hospital setting.

Methods

A case-control study was conducted among 4,964 Kaiser Permanente patients diagnosed with node-negative invasive breast cancer from 1985 to 1994 and not treated with adjuvant chemotherapy. Cases (n = 220) were patients who died from breast cancer. Controls (n = 570) were breast cancer patients who were individually matched to cases with respect to age, race, adjuvant tamoxifen, medical fac

SUBMITTER: Habel LA 

PROVIDER: S-EPMC1557737 | biostudies-literature | 2006

REPOSITORIES: biostudies-literature